Home
REGENXBIO

REGENXBIO Market Share Analysis for August 2026

Health > Biotechnology and Pharmaceuticals

Domainregenxbio.com

Year Founded2008

Employees201 - 500

Annual Revenue$100M - $200M

REGENXBIO

REGENXBIO (including company regionals)

regenxbio.com

See more website traffic and engagement information

REGENXBIO Revenue up to August 2026 is 100M - 200M

revenue generated by REGENXBIO top domains

REGENXBIO top domains revenue over 3 years

Revenue for REGENXBIO top domains

regenxbio.com100M - 200M

See more with Sales Intelligence

Total visits to REGENXBIO's top domains

Understand REGENXBIO market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

regenxbio.com14K

See more with Sales Intelligence

Avg. visit duration in REGENXBIO's top domains

Analyze REGENXBIO engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

regenxbio.com00:00:23

See more with Sales Intelligence

Avg. pageviews on REGENXBIO's top domains

See how REGENXBIO keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

regenxbio.com1.58

See more with Sales Intelligence

REGENXBIO top competitors by domain

Top similar sites in August 2026, ranked by their affinity

askbio.comCompany NameAskBioEmployees501 - 1000HQUnited States, North Carolina, DurhamAnnual revenue$15M - $25MTotal visits11.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by REGENXBIO

These are the website technologies, by industry, used by REGENXBIO top domains

Widget (11)

Twemoji

Conversion & Analytics (3)

Google Analytics

Social (3)

Google+ Platform

Content Management System (2)

WordPress

More Technologies

10

See all

News & Signals from REGENXBIO

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsREGENXBIO Inc. had issues with alleged breaches of fiduciary duty on Feb 9th '22.Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty.

NewsREGENXBIO Inc. partners with NS Pharma, Inc..REGENXBIO and partner NS Pharma are reviewing additional imaging and long-term follow-up data while incorporating FDA feedback into future plans.

NewsREGENXBIO Inc. had revenue of $108M on Aug 21st '26.* REGENXBIO beat quarterly expectations, reporting $0.43 in EPS versus the $0.08 consensus and revenue of $108.02 million versus estimates of $97.63 million.